Immunorizon, previously named ExploreBio1, was founded in late 2017, and is developing conditionally activated Tumor-Restricted T-and NK-Cell Engagers for cancer therapy. The company extends its pipeline and differentiate by using tri-specific constructs with additional tumor associated antigens and diverse engagers with both T-cells and NK-cells. The company operates out of Israel.